Clinical Trial Update: The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19 [Phase 2]

View source ↗

Summary

The ARCTIC trial investigating aerosolized inhaled adenosine for acute respiratory distress syndrome caused by COVID-19 (Phase 2) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Adenosine (inhaled aerosol) (adenosine)

Snippet

Sponsor: University of Florida | Conditions: Acute Respiratory Distress | Phase 2 | Status: WITHDRAWN